Sign in

CIK 0001404644

  • Non-accelerated filer
  • Smaller reporting company

Neurogene Inc.

Sign in to watch
Ticker
NGNE
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
FY end
Dec 31
Entity type
Operating
EIN
980542593
Phone
+1 877-237-5020
Business address
535 W 24TH STREET, 5TH FLOOR, NEW YORK, NY, 10011
Former names
Neoleukin Therapeutics, Inc., AQUINOX PHARMACEUTICALS, INC, AQUINOX PHARMACEUTICALS (USA) INC
Open-market buys, last 90 days
$0
in 0 filings
Open-market sales, last 90 days
$0
in 0 filings

Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.

Reading 38 more Form 4s from the SEC; this list fills in as they're read.

Date Insider Transaction Shares Price Value Owned after
2018-08-07 Main David President and CEO Grant or award · Stock Option (Right to Buy) +415,000 415,000
2018-03-09 Main David President and CEO Grant or award · Stock Option (Right to Buy) +225,000 225,000
2017-06-05 Main David President and CEO Exercise or conversion +3,625 $9.60 $35K 75,155
2017-06-05 Main David President and CEO Sale −3,625 $13.16 $48K 71,530
2017-06-05 Main David President and CEO Exercise or conversion · Stock Option (Right to Buy) −3,625 0
2017-06-02 Main David President and CEO Exercise or conversion +6,000 $9.60 $58K 77,530
2017-06-02 Main David President and CEO Sale −6,000 $13.59 $82K 71,530
2017-06-02 Main David President and CEO Exercise or conversion · Stock Option (Right to Buy( −6,000 3,625
2017-06-01 Main David President and CEO Exercise or conversion +6,000 $9.60 $58K 77,530
2017-06-01 Main David President and CEO Sale −6,000 $13.00 $78K 71,530
2017-06-01 Main David President and CEO Exercise or conversion · Stock Option (Right to Buy) −6,000 9,625
2017-03-08 Main David President and CEO Grant or award · Stock Option (Right to Buy) +185,000 185,000
2016-03-10 Main David President and CEO Grant or award · Stock Option (Right to Buy) +120,000 120,000

Page 1 of 1 · 13 trades